DOCSLIB.ORG

Somatically Mutated Regions of Immunoglobulin on Human B-Cell

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Somatically Mutated Regions of Immunoglobulin on Human B-Cell [CANCER RESEARCH 61, 5145–5152, July 1, 2001] Somatically Mutated Regions of Immunoglobulin on Human B-Cell Lymphomas Code for Peptides That Bind to Autologous Major Histocompatibility Complex Class I, Providing a Potential Target for Cytotoxic T Cells1 Clair S. Gricks, Eira Rawlings, Letizia Foroni, J. Alejandro Madrigal, and Peter L. Amlot2 Departments of Immunology [C. S. G., E. R., P. L. A.] and Haematology [L. F., J. A. M.], Royal Free and University College Medical School, London NW3 2PF, United Kingdom ABSTRACT (10). Alternatively, immunization with idiotypic proteins or DNA vaccines without adjuvant produced low levels of idiotypic antibody Lymphoma-derived immunoglobulin idiotype (Id) is a well-character- and poor protective immunity in mice and humans (10, 11). Addition ized, tumor-specific antigen on B-cell malignancies. Immunotherapy using lymphoma immunoglobulin can lead to clinical responses mostly associ- of an adjuvant, for example tetanus toxin fragment C, to DNA ated with anti-Id antibody. We cloned the Id from B-cell lymphomas, encoding the idiotype induced higher levels of idiotypic antibodies in sequenced them, and used bioinformatics to select autologous MHC class mice (12), and this approach is currently being tested in humans. I binding peptides from somatically mutated regions of the lymphoma Id. Although the vast majority of studies have used anti-idiotype antibody Peptides from patients who were HLA-A1, HLA-A2, HLA-A3, or HLA- as an indicator of immune response, more recent work has focused on A11 positive were analyzed in the T2 stabilization assay and a competitive the generation of specific cellular immunity. Immunization of follic- peptide-binding assay. By both methods, approximately half of the pep- ular lymphoma patients with idiotypic protein plus granulocyte/ tides analyzed, regardless of HLA type, bound with intermediate or high macrophage-colony stimulating factor, induced secretion of tumor affinity. Peptide binding affinity was similar to viral peptide sequences known to provide targets for cytotoxic T cells. Further investigation of necrosis factor from postvaccine PBMCs, shown to be mediated by ϩ ϩ lymphocyte responses to stimulation by autologous Id peptides versus Id CD4 and CD8 T cells (13). Specific lysis of autologous tumor cells peptides from other patients revealed that three of five patients in com- was also observed and was blocked by antibodies against MHC class plete remission or with low volume, stable disease responded to self- I, indicating the role of CD8ϩ cytotoxic T cells. Immunization of peptides by IFN-␥ secretion greater than that seen with non-self peptides, lymphoma patients with idiotype protein-pulsed autologous dendritic whereas none of five patients with progressive disease responded to their cells induced cellular proliferative responses rather than humoral own lymphoma Id. We have shown that mutated regions of lymphoma Id immunity (14). A large body of evidence favors cell-mediated rather contain MHC class I binding peptides that are potential targets for cytotoxic T cells. Immunotherapy using the tumor-specific mutated re- than antibody control of tumors, and this is supported by studies in gions from lymphoma Id avoids the need to break innate tolerance toward melanoma (15, 16) and virally induced tumors (17). the germ-line protein sequences present on normal and malignant B cells. The increased knowledge of epitopes within tumor-associated pro- teins recognized by CTL and bioinformatics enabling prediction of peptide binding to HLA class I have provided tools with which to INTRODUCTION search for the existence of CTLs and immunogenic peptides within Immunotherapy of human cancers requires suitably immunogenic, tumors from patients with malignancy (16, 18, 19). This approach has tumor-specific or -associated antigens. Surface immunoglobulin pro- also been used to monitor CTL responses in patients infected with vides a tumor-specific target in patients with B-cell malignancies viruses such as cytomegalovirus and EBV (20, 21). A recent study by because of its unique method of synthesis (1). The random insertion Trojan et al. (22) described HLA-A2-restricted peptide epitopes from of nucleotides between V(D)J gene segments during antigen-indepen- the tumor-derived immunoglobulin variable region from patients dent rearrangement of immunoglobulin genes followed by somatic mainly with CLL. Some of the peptides were shared among patients, hypermutation, occurring in germinal centers as a result of antigen indicating their unmutated, germ-line nature. The authors described stimulation, leads to immunoglobulin sequences not coded in the the in vitro generation of donor and some patient CTLs against the germ-line DNA (2, 3). The unique variable region of rearranged peptides and reported low-level killing of CLL tumor cells. immunoglobulin is known as its Id.3 Follicular lymphomas and my- The aims of our study were to define peptide sequences from elomas have a high rate of somatic hypermutation (4–7), which somatically mutated regions in lymphoma immunoglobulin Ids capa- increases the probability that their Ids will be immunogenic. ble of binding to the patient’s own HLA class I molecules and Immunization with idiotypic protein and adjuvant induces anti- hypothetically with a greater immunogenicity, because the mutated idiotypic antibodies in both mice (8) and humans in the absence of regions should not be regarded as self. The mutant cell line, T2, clinically detectable lymphoma (9), indicating the immunogenic po- provided a means of testing peptide binding to the HLA-A2 allele by tential of Ids. The production of anti-idiotypic antibodies has been the ability to up-regulate and stabilize cell surface expression of shown to mediate protection against tumor challenge in mouse models HLA-A2 peptide complexes (23). In addition, peptides of lymphoma Ids from patients with HLA-A3 were tested on a T2 cell line trans- Received 1/21/01; accepted 5/1/01. fected with HLA A3 (24). Selected peptides restricted by A1, A2, A3, The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with and A11 were also tested for binding in a competitive inhibition assay 18 U.S.C. Section 1734 solely to indicate this fact. using either LCLs derived from the patients themselves or LCLs 1 Supported in part by the Leukaemia Research Fund (to E. R.) and by the Marc Fisher homozygous for the HLA type of interest. Finally, stimulation of Trust (to C. S. G.). 2 To whom requests for reprints should be addressed, at Department of Immunology, patient lymphocytes by their own idiotypic peptides was examined in Royal Free and University College Medical School, Rowland Hill Street, London NW3 ELISPOT assays. The demonstration of frequent self-HLA binding 2PF. Phone: 44-20-7472-6266; Fax: 44-20-7431-3416; E-mail: [email protected]. 3 The abbreviations used are: Id, idiotype; PBMC, peripheral blood mononuclear cell; lymphoma idiotypic peptides and lymphocytes from lymphoma pa- CLL, chronic lymphocytic leukemia; LCL, lymphoblastoid cell line; ELISPOT, enzyme- tients in long-term remission capable of reacting to idiotypic peptides linked immunospot; RT-PCR, reverse transcription-PCR; MFI, mean fluorescence inten- ␥ sity; FR, framework region; CDR, complementarity-determining region; DLBL, diffuse by IFN- secretion suggests that mutated idiotypic peptides provide a large B-cell lymphoma; FCL, follicle center lymphoma. target for control of lymphomas by cell-mediated immune responses. 5145 Downloaded from cancerres.aacrjournals.org on September 24, 2021. © 2001 American Association for Cancer Research. LYMPHOMA IDIOTYPIC PEPTIDE BINDING TO MHC CLASS I MATERIALS AND METHODS A2, A3, or A11 (cell lines JY, HOM-1, VAVY, and FB) or the patient’s own B-LCL were washed twice in PBS and left to rest as a pellet on ice for 5 min. Patients. Lymphoma patients were classified according to the REAL clas- The cells were then acid stripped for 90 s using ice-cold Na2HPO4 buffer, pH sification (25). Lymphoid tissue was analyzed from 17 patients with diffuse 3.1 for A1, pH 3.2 for A2, and pH 2.9 for A3 and A11. The cells were buffered large cell lymphoma, 16 with follicle center lymphoma, 6 with B-cell small with ice-cold Iscove’s modified Dulbecco’s medium (ICN Flow, Basingstoke, lymphocytic lymphoma, 2 with mantle cell lymphoma, 2 with marginal zone Hampshire, United Kingdom), and then washed and resuspended at 1 ϫ 106/ml lymphoma, 1 with plasma cell myeloma, and 1 with lymphoplasmacytoid ␮ ␤ in Iscove’s modified Dulbecco’s medium plus 7.5 g/ml 2-microglobulin lymphoma. All patients were referred to our institution and treated according (Cymbus Biotechnology Ltd.). Twenty-five ␮l of fluorescent-labeled reference to United Kingdom standard lymphoma protocol. peptide [HLA-A1, YLEPACFITCAKY; HLA-A2, FLPSDCFITCFPSV; HLA- Genomic DNA Isolation. Diagnostic biopsies from 45 patients with B-cell A3/11, KVFPCFITCALINK (Department of Immunohematology and Blood malignant lymphomas were processed for DNA extraction using Proteinase K Bank, Leiden University Medical Center)] at a final concentration of 133 nM and a Puregene kit (Flowgen, Lichfield, Staffordshire, United Kingdom). were incubated with 25 ␮l of Id competitor peptide (MWG-Biotech) at final Patients were assessed for IgH clonality by Southern blotting and hybridization concentrations of 0.5–33.3 ␮M in a 96-well, U-bottomed plate with 100 ␮l to a JH probe, as described previously (26, 27). Patients with clonal JH pattern (1 ϫ 105) of cells for 24 h at 4°C (42). The percentage inhibition demonstrated were processed for amplification of the rearranged IgH genes as detailed by immunoglobulin peptides competing with the FITC-labeled reference pep- below. tide was calculated as described (42). PCR. PCR was performed using the manufacturer’s instruction (Promega, ELISPOT Assay for IFN-␥. PBMCs (1 ϫ 105) were plated in triplicate in Southampton, United Kingdom) in a 30-␮l volume containing 1 ␮g of genomic round-bottomed, 96-well plates and stimulated for 18 h with 50 ␮g/ml peptide DNA and 100 pM of each primer.
Load more

Recommended publications
  • 1 the Immune System
    1 The immune system The immune response Innate immunity Adaptive immunity The immune system comprises two arms (rapid response) (slow response) functioning cooperatively to provide a Dendritic cell Mast cell comprehensive protective response: the B cell innate and the adaptive immune system. Macrophage γδ T cell T cell The innate immune system is primitive, does not require the presentation of an antigen, Natural and does not lead to immunological memory. killer cell Basophil Its effector cells are neutrophils, Complement protein macrophages, and mast cells, reacting Antibodies Natural Eosinophil killer T cell CD4+ CD8+ within minutes to hours with the help of T cell T cell complement activation and cytokines (CK). Granulocytes Neutrophil B-lymphocytes B-cell receptor The adaptive immune response is provided by the lymphocytes, which precisely recognise unique antigens (Ag) through cell-surface receptors. epitope Receptors are obtained in billions of variations through antigen cut and splicing of genes and subsequent negative T-lymphocytes selection: self-recognising lymphocytes are eradicated. T-cell receptor Immunological memory after an Ag encounter permits a faster and heightened state of response on a subsequent exposure. epitope MHC Lymphocytes develop in primary lymphoid tissue (bone marrow [BM], thymus) and circulate towards secondary Tonsils and adenoids Lymph lymphoid tissue (lymph nodes [LN], spleen, MALT). nodes Lymphatic vessels The Ag reach the LN carried by lymphocytes or by Thymus dendritic cells. Lymphocytes enter the LN from blood Lymph transiting through specialised endothelial cells. nodes The Ag is processed within the LN by lymphocytes, Spleen macrophages, and other immune cells in order to mount a specific immune response.
    [Show full text]
  • Somatic Hypermutation Targeting to Intrinsic Hotspots of Immunoglobulin
    Leukemia (2001) 15, 1772–1778 2001 Nature Publishing Group All rights reserved 0887-6924/01 $15.00 www.nature.com/leu Somatic hypermutation targeting to intrinsic hotspots of immunoglobulin genes in follicular lymphoma and multiple myeloma C Belessi1, K Stamatopoulos2, N Stavroyianni2, K Zoi2, T Papadaki3 and C Kosmas4 1Hematology Laboratory, General Hospital of Nikea, Piraeus; 2First Department of Medicine, Athens University School of Medicine, Laikon General Hospital, Athens; 3Hemopathology Unit, Evangelismos Hospital, Athens; and 4Department of Medicine, Helena Venizelou Hospital, Athens, Greece In this study, we analyzed the targeting of the somatic hyper- of the secondary lymphoid organs where contact with and mutation (SHM) mechanism at specific hotspot sequence 3 ␬ selection by antigen takes place. The molecular hallmark of motifs in the VH and V genes of 10 follicular lymphoma (FL) cases and the V␬ and V␭ genes of 11 ␬- and six ␭-light chain this phase is the introduction of mutations within rearranged expressing multiple myeloma (MM) cases. These sequences IgV genes, at a rate much higher than usual, a phenomenon were analyzed for targeting of specific motifs, ie certain highly described as somatic hypermutation.4 mutable trinucleotides (3-NTPs), the tetranucleotide (4-NTP) Antigen selection in B cell ontogeny is evidenced by non- RGYW and its complementary, WRCY (where R = purine, random distribution of somatic mutations in lg HC and LC V = = Y pyrimidine and W A or T). Comparisons were carried out genes, a feature providing useful information concerning the between mutation frequencies in RGYW vs WRCY and the inci- 5 dence of mutations in complementarity determining region ontogenetic assignment of B cell neoplastic disorders.
    [Show full text]
  • Somatic Hypermutation of T Cell Receptor a Chain Contributes To
    RESEARCH ARTICLE Somatic hypermutation of T cell receptor a chain contributes to selection in nurse shark thymus Jeannine A Ott1, Caitlin D Castro2, Thaddeus C Deiss1, Yuko Ohta2, Martin F Flajnik2, Michael F Criscitiello1,3* 1Comparative Immunogenetics Laboratory, Department of Veterinary Pathobiology, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, Texas, United States; 2Department of Microbiology and Immunology, University of Maryland at Baltimore, Baltimore, United States; 3Department of Microbial Pathogenesis and Immunology, College of Medicine, Texas A&M Health Science Center, Texas A&M University, Texas, United States Abstract Since the discovery of the T cell receptor (TcR), immunologists have assigned somatic hypermutation (SHM) as a mechanism employed solely by B cells to diversify their antigen receptors. Remarkably, we found SHM acting in the thymus on a chain locus of shark TcR. SHM in developing shark T cells likely is catalyzed by activation-induced cytidine deaminase (AID) and results in both point and tandem mutations that accumulate non-conservative amino acid replacements within complementarity-determining regions (CDRs). Mutation frequency at TcRa was as high as that seen at B cell receptor loci (BcR) in sharks and mammals, and the mechanism of SHM shares unique characteristics first detected at shark BcR loci. Additionally, fluorescence in situ hybridization showed the strongest AID expression in thymic corticomedullary junction and medulla. We suggest that TcRa utilizes SHM to broaden diversification of the primary ab T cell repertoire in sharks, the first reported use in vertebrates. DOI: https://doi.org/10.7554/eLife.28477.001 *For correspondence: [email protected] Competing interests: The Introduction authors declare that no competing interests exist.
    [Show full text]
  • Allergic Rhinitis Patients of Switch Recombination in the Nasal Mucosa Local Somatic Hypermutation and Class
    Local Somatic Hypermutation and Class Switch Recombination in the Nasal Mucosa of Allergic Rhinitis Patients This information is current as Heather A. Coker, Stephen R. Durham and Hannah J. Gould of September 23, 2021. J Immunol 2003; 171:5602-5610; ; doi: 10.4049/jimmunol.171.10.5602 http://www.jimmunol.org/content/171/10/5602 Downloaded from References This article cites 33 articles, 7 of which you can access for free at: http://www.jimmunol.org/content/171/10/5602.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on September 23, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2003 by The American Association of Immunologists All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Local Somatic Hypermutation and Class Switch Recombination in the Nasal Mucosa of Allergic Rhinitis Patients Heather A. Coker,1* Stephen R. Durham,† and Hannah J. Gould2* Immunoglobulin E is produced by nasal B cells in response to allergen.
    [Show full text]
  • B-Helper Neutrophils in Regional Lymph Nodes Correlate with Improved Prognosis in Patients with Head and Neck Cancer
    cancers Article B-Helper Neutrophils in Regional Lymph Nodes Correlate with Improved Prognosis in Patients with Head and Neck Cancer Ekaterina Pylaeva 1,† , Irem Ozel 1,† , Anthony Squire 2, Ilona Spyra 1, Charlotte Wallner 1, Magdalena Korek 1, Georg Korschunow 1, Maksim Domnich 1 , Elena Siakaeva 1, Moritz Goetz 3, Agnes Bankfalvi 3, Stephan Lang 1,4, Benjamin Kansy 1,4,*,‡ and Jadwiga Jablonska 1,4,*,‡ 1 Department of Otorhinolaryngology, University Hospital Essen, University Duisburg-Essen, 45147 Essen, Germany; [email protected] (E.P.); [email protected] (I.O.); [email protected] (I.S.); [email protected] (C.W.); [email protected] (M.K.); [email protected] (G.K.); [email protected] (M.D.); [email protected] (E.S.); [email protected] (S.L.) 2 Institute of Experimental Immunology and Imaging, University Hospital Essen, University Duisburg-Essen, 45141 Essen, Germany; [email protected] 3 Institute of Pathology, University Hospital Essen, University of Duisburg-Essen, 45147 Essen, Germany; [email protected] (M.G.); [email protected] (A.B.) 4 German Cancer Consortium (DKTK) Partner Site Düsseldorf/Essen, 45147 Essen, Germany * Correspondence: [email protected] (B.K.); [email protected] (J.J.) † These authors contributed equally. ‡ These authors contributed equally. Simple Summary: Neutrophils exhibit multiple functions during cancer progression and are believed Citation: Pylaeva, E.; Ozel, I.; Squire, to regulate adaptive immune responses to cancer. In addition to their interactions with T cells in A.; Spyra, I.; Wallner, C.; Korek, M.; this context, these cells are also believed to interact with B cells.
    [Show full text]
  • A Natural Killer Cell-Centric Approach Toward New Therapeutics For
    A natural killer cell-centric approach toward new therapeutics for autoimmune disease A dissertation submitted to the Graduate School of the University of Cincinnati in partial fulfillment of the requirements for the degree of Doctor of Philosophy (Ph.D.) in the Immunology Graduate Training Program of the College of Medicine 2019 By Seth D. Reighard B.S., University of Pittsburgh, 2010 Thesis Advisor: Stephen N. Waggoner, Ph.D. Dissertation Committee Chair: William M. Ridgway, M.D. 1 Abstract The debilitating autoimmune disease systemic lupus erythematosus (SLE) is the 5th leading cause of death for African American and Hispanic women between 15 and 24 years of age. Current therapeutics for SLE are blunt weapons that broadly suppress a patient’s immune system, and only one new treatment option has been approved in over 50 years. Standard treatments for SLE potentially lack efficacy because they do not specifically target the immune dysfunction underlying disease. SLE is characterized by the abnormal production of self-targeting autoantibodies that cause widespread organ damage. SLE autoantibodies are generated by rampant germinal center (GC) reactions: immune processes wherein memory B cells and antibody secreting cells (ASC) arise from naïve B lymphocytes following clonal expansion, somatic hypermutation, affinity maturation, and antibody class switching while receiving critical help from follicular helper T (TFH) cells. We hypothesize that inhibition of TFH and GC responses in SLE may be accomplished by harnessing the therapeutic potential of the natural killer (NK) cell. Though classically implicated in anti-tumor and antiviral immunity, NK cells also suppress activated TFH, resulting in reduced GC reactions and decreased antibodies.
    [Show full text]
  • Of B Cells in Vitro Signals That Initiate Somatic Hypermutation
    Signals That Initiate Somatic Hypermutation of B Cells In Vitro1 Sigridur Bergthorsdottir,* Aoife Gallagher,2* Sandra Jainandunsing,* Debra Cockayne,† James Sutton,* Tomas Leanderson,‡ and David Gray2,3* Somatic hypermutation is initiated as B lymphocytes proliferate in germinal centers. The signals that switch on the mutation process are unknown. We have derived an in vitro system to define signals that will initiate mutation in normal, naive splenic B cells. We find that three signals are required to allow detection of somatic mutation in vitro; these are anti-Ig, anti-CD40, and anti-CD38. If any one of these is omitted, mutation remains off. We show that CD40 is obligatory in vivo, as CD40 knockout mice exhibit no Ag-driven mutation. In contrast, CD38 is not, as CD38 knockout mice mutate normally. We believe that, in vitro, CD38, in combination with other stimuli, drives extensive cell division, allowing the detection of mutated sequences. However, in germinal centers in vivo, proliferative activity is instigated by a different molecule. This is the first demonstration of the initiation of hypermutation in vitro with normal splenic B cells using defined stimuli. The Journal of Immunology, 2001, 166: 2228–2234. ffinity maturation of the Ab response occurs largely as a liferation, or what causes differentiation within the GC (e.g., the result of selection of the Ig V gene products that have transition of centroblast to centrocyte). CD40 is implicated in the A undergone a process of somatic hypermutation. The vast first two functions as CD40 knockout mice develop no GC (8, 9); majority of late primary and secondary response Abs exhibit however, its role in GC induction may be an indirect one as rudi- changes from the germline V sequence (1, 2), and most memory B mentary GC can be regenerated in these mice simply by injection 4 cells carry somatically mutated B cell receptors (BCR) (3).
    [Show full text]
  • Regulation of AID, the B-Cell Genome Mutator
    Downloaded from genesdev.cshlp.org on September 25, 2021 - Published by Cold Spring Harbor Laboratory Press REVIEW Regulation of AID, the B-cell genome mutator Celia Keim, David Kazadi, Gerson Rothschild, and Uttiya Basu1 Department of Microbiology and Immunology, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA The mechanisms by which B cells somatically engineer (Huang et al. 2005), and macrophages (Koppel et al. 2005), their genomes to generate the vast diversity of antibodies the latter two of which derive from CMP cells and are required to challenge the nearly infinite number of produced during the sentinel innate immune response. antigens that immune systems encounter are of tremen- Dendritic cells and macrophages travel to the site of an dous clinical and academic interest. The DNA cytidine infection and function as phagocytic cells (macrophages) deaminase activation-induced deaminase (AID) catalyzes or as cells specialized in taking up antigens and present- two of these mechanisms: class switch recombination ing peptide fragments to lymphocytes for recognition (CSR) and somatic hypermutation (SHM). Recent discov- (dendritic cells). Briefly, then, the HSC-derived myeloid eries indicate a significant promiscuous targeting of this progenitor macrophages and dendritic cells present anti- B-cell mutator enzyme genome-wide. Here we discuss gens to the HSC-derived lymphoid progenitor B and T the various regulatory elements that control AID activ- cells, allowing the immune response to proceed. CMP ity and prevent AID from inducing genomic instability cells are not restricted to just phagocytic or antigen and thereby initiating oncogenesis. presentation roles, however, as they also encompass members of the granulocyte and mast cell lineages.
    [Show full text]
  • Somatic Hypermutation of the New Antigen Receptor Gene (NAR)
    Proc. Natl. Acad. Sci. USA Vol. 95, pp. 14343–14348, November 1998 Immunology, Evolution Somatic hypermutation of the new antigen receptor gene (NAR) in the nurse shark does not generate the repertoire: Possible role in antigen-driven reactions in the absence of germinal centers MARILYN DIAZ,ANDREW S. GREENBERG, AND MARTIN F. FLAJNIK* University of Miami School of Medicine, Department of Microbiology and Immunology, Miami, FL 33136 Communicated by Masatoshi Nei, Pennsylvania State University, University Park, PA, October 2, 1998 (received for review July 7, 1998) ABSTRACT The new antigen receptor (NAR) gene in the to generate the repertoire in some species; studies of somatic nurse shark diversifies extensively by somatic hypermutation. It hypermutation in the cartilaginous fish address this issue. is not known, however, whether NAR somatic hypermutation In the nurse shark, Ginglymostoma cirratum, a new class of generates the primary repertoire (like in the sheep) or rather is antigen receptor gene (NAR) was discovered in our laboratory. used in antigen-driven immune responses. To address this issue, NAR is a covalently linked dimer, each monomer consisting of the sequences of NAR transmembrane (Tm) and secretory (Sec) one V domain and five constant (C) domains. NAR is found in forms, presumed to represent the primary and secondary rep- both transmembrane (Tm) and secretory (Sec) forms, but it ertoires, respectively, were examined from the peripheral blood differs from bona fide Ig in that it does not associate with Ig light lymphocytes of three adult nurse sharks. More than 40% of the chains (2, 12). Further, the NAR V region is more similar to Ig y Sec clones but fewer than 11% of Tm clones contained five light chain T-cell receptor V than to Ig heavy chain V (2).
    [Show full text]
  • Activation-Induced Cytidine Deaminase (AID) Linking Immunity, Chronic Inflammation, and Cancer
    Cancer Immunol Immunother (2012) 61:1591–1598 DOI 10.1007/s00262-012-1255-z SYMPOSIUM-IN-WRITING PAPER Activation-induced cytidine deaminase (AID) linking immunity, chronic inflammation, and cancer Diana Mechtcheriakova • Martin Svoboda • Anastasia Meshcheryakova • Erika Jensen-Jarolim Received: 12 January 2012 / Accepted: 27 March 2012 / Published online: 19 April 2012 Ó The Author(s) 2012. This article is published with open access at Springerlink.com Abstract Activation-induced cytidine deaminase (AID) of fundamental aspects is still lacking as (1) what are the is critically involved in class switch recombination and crucial factors triggering an aberrant AID expression/ somatic hypermutation of Ig loci resulting in diversification activity including the impact of Th2-driven inflammation of antibodies repertoire and production of high-affinity and (2) to what extent may aberrant AID in human non-B antibodies and as such represents a physiological tool to cells lead to abnormal cell state associated with an introduce DNA alterations. These processes take place increased rate of genomic alterations as point mutations, within germinal centers of secondary lymphoid organs. small insertions or deletions, and/or recurrent chromosomal Under physiological conditions, AID is expressed pre- translocations during solid tumor development and dominantly in activated B lymphocytes. Because of the progression. mutagenic and recombinogenic potential of AID, its expression and activity is tightly regulated on different Keywords Activation-induced cytidine deaminase Á levels to minimize the risk of unwanted DNA damage. Gene network Á Inflammation Á Cancer Á Multigene However, chronic inflammation and, probably, combina- signature approach Á AllergoOncology tion of other not-yet-identified factors are able to create a symposium-in-writing microenvironment sufficient for triggering an aberrant AID expression in B cells and, importantly, in non-B-cell background.
    [Show full text]
  • Defect in Igv Gene Somatic Hypermutation in Common Variable Immuno-Deficiency Syndrome
    Proc. Natl. Acad. Sci. USA Vol. 95, pp. 13135–13140, October 1998 Immunology Defect in IgV gene somatic hypermutation in Common Variable Immuno-Deficiency syndrome YVES LEVY*†‡,NEETU GUPTA†,FRANC¸OISE LE DEIST§,CORINNE GARCIA†,ALAIN FISCHER§,JEAN-CLAUDE WEILL†, AND CLAUDE-AGNE`S REYNAUD† *Unite´d’immunologie clinique, Hoˆpital Henri Mondor, 51, avenue du Mare´chalde Lattre de Tassigny, 94010 Cre´teilCedex 10, France; †Institut National de la Sante´et de la Recherche Me´dicaleUnite´373, Faculte´deMe´decine Necker-Enfants Malades, 156, rue de Vaugirard, 75730 Paris Cedex 15, France; and §Institut National de la Sante´et de la Recherche Me´dicaleUnite´429, Hoˆpital Necker-Enfants Malades, 149, rue de Se`vres, 75730 Paris Cedex 15, France Edited by Max D. Cooper, University of Alabama, Birmingham, AL, and approved September 8, 1998 (received for review June 8, 1998) ABSTRACT Common Variable Immuno-Deficiency from eight patients (six CVID and 2 hypogammaglobulinemic (CVID) is the most common symptomatic primary antibody- patients with recurrent infections). In two CVID cases, 40 to 75% deficiency syndrome, but the basic immunologic defects under- of the pool of circulating IgG memory B cells were found totally lying this syndrome are not well defined. We report here that devoid of somatic mutation, suggesting that the process of Ig among eight patients studied (six CVID and two hypogamma- affinity maturation can be severely hampered in some CVID globulinemic patients with recurrent infections), there is in two patients. Finally, functional analysis of the T cell compartment, CVID patients a dramatic reduction in Ig V gene somatic including an in vitro assay of the capacity of peripheral T cells to hypermutation with 40–75% of IgG transcripts totally devoid of induce somatic hypermutation in a human B cell line, argues in mutations in the circulating memory B cell compartment.
    [Show full text]
  • Somatic Hypermutation of the New Antigen Receptor Gene
    Proc. Natl. Acad. Sci. USA Vol. 95, pp. 14343–14348, November 1998 Immunology, Evolution Somatic hypermutation of the new antigen receptor gene (NAR) in the nurse shark does not generate the repertoire: Possible role in antigen-driven reactions in the absence of germinal centers MARILYN DIAZ,ANDREW S. GREENBERG, AND MARTIN F. FLAJNIK* University of Miami School of Medicine, Department of Microbiology and Immunology, Miami, FL 33136 Communicated by Masatoshi Nei, Pennsylvania State University, University Park, PA, October 2, 1998 (received for review July 7, 1998) ABSTRACT The new antigen receptor (NAR) gene in the to generate the repertoire in some species; studies of somatic nurse shark diversifies extensively by somatic hypermutation. It hypermutation in the cartilaginous fish address this issue. is not known, however, whether NAR somatic hypermutation In the nurse shark, Ginglymostoma cirratum, a new class of generates the primary repertoire (like in the sheep) or rather is antigen receptor gene (NAR) was discovered in our laboratory. used in antigen-driven immune responses. To address this issue, NAR is a covalently linked dimer, each monomer consisting of the sequences of NAR transmembrane (Tm) and secretory (Sec) one V domain and five constant (C) domains. NAR is found in forms, presumed to represent the primary and secondary rep- both transmembrane (Tm) and secretory (Sec) forms, but it ertoires, respectively, were examined from the peripheral blood differs from bona fide Ig in that it does not associate with Ig light lymphocytes of three adult nurse sharks. More than 40% of the chains (2, 12). Further, the NAR V region is more similar to Ig y Sec clones but fewer than 11% of Tm clones contained five light chain T-cell receptor V than to Ig heavy chain V (2).
    [Show full text]